6FK.F GENTIAN DIAGNOST. NO -01
- Market cap
- EUR 57.2M
- P/E
- -
- P/B
- 3.18x
- ROE
- -6.0%
- Dividend yield
- 1.52%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 6FK.F undervalued?
Graham numberThe Graham number of GENTIAN DIAGNOST. NO -01 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
GENTIAN DIAGNOST. NO -01 fundamental analysis
No fundamental analysis for GENTIAN DIAGNOST. NO -01 yet.
GENTIAN DIAGNOST. NO -01 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About GENTIAN DIAGNOST. NO -01
Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. It offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Calprotectin Immunoassay, a turbidimetric assay used for the measurement of circulating calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a GFR marker for th…
Full company profileGENTIAN DIAGNOST. NO -01 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
GENTIAN DIAGNOST. NO -01 annual financial statements (NOK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 102M | 135M | 152M | 176M | 193M |
| Gross Profit | 49.0M | 64.2M | 82.8M | 98.2M | 109M |
| Operating Income | -23.2M | -12.8M | 15.7M | 25.5M | -13.7M |
| EBITDA | -12.1M | -5.00K | 29.7M | 35.5M | 293K |
| Net Income | -23.6M | -10.6M | 45.3M | 13.3M | -11.4M |
| EPS | -1.53 | -0.69 | 2.94 | 0.86 | -0.74 |
| Balance Sheet | |||||
| Total Assets | 188M | 181M | 230M | 259M | 234M |
| Total Liabilities | 33.6M | 34.4M | 35.6M | 53.6M | 43.5M |
| Shareholders' Equity | 154M | 147M | 194M | 205M | 191M |
| Cash & Short-term Investments | 81.6M | 87.6M | 84.7M | 106M | 91.4M |
| Cash Flow | |||||
| Operating Cash Flow | -14.0M | 15.5M | 13.5M | 42.6M | -1.24M |
| Capital Expenditure | 14.7M | 4.49M | 11.0M | 10.8M | 3.02M |
| Free Cash Flow | -28.6M | 11.0M | 2.51M | 31.8M | -4.27M |
| Ratios | |||||
| ROE | -15.3% | -7.3% | 23.3% | 6.5% | -6.0% |
| ROA | -12.6% | -5.9% | 19.7% | 5.1% | -4.9% |
| Net Profit Margin | -23.2% | -7.9% | 29.8% | 7.5% | -5.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
GENTIAN DIAGNOST. NO -01 dividends
- Dividend yield
- 1.52%
- Forward dividend
- 0.06 EUR
- Payout ratio
- 46.5%
- Ex-dividend date
- May 6, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | NOK 6.17M | 0.40 | 46.5% |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns GENTIAN DIAGNOST. NO -01
- Insiders 50.04%
- Institutions 32.66%
- Public & others 17.30%
- Shares outstanding 15.5M
- Free float 7.28M
GENTIAN DIAGNOST. NO -01 company profile
- Company name
- GENTIAN DIAGNOST. NO -01
- Ticker
- 6FK.F
- ISIN
- NO0010748866
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 63
- Fiscal year end
- December
- Address
- BjOernAsveien 5, Moss, Norway, 1596
- Phone
- 47 99 33 99 05
- Website
- gentian.com
About GENTIAN DIAGNOST. NO -01
Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. It offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Calprotectin Immunoassay, a turbidimetric assay used for the measurement of circulating calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a GFR marker for the diagnosis and therapeutic control of renal function and chronic kidney disease; Gentian Retinol-Binding Protein Immunoassay for detection of retinol-binding protein in human serum and plasma; and Canine CRP Immunoassay test kit, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine C-reactive protein in dog plasma and serum. The company also develops faecal calprotectin immunoassay turbo that offers results of calprotectin concentration in stool supporting diagnosis of inflammatory bowel disease; and faecal pancreatic elastase immunoassay turbo, which allows analysis of pancreatic elastase in stool to aid in diagnosis of pancreatic exocrine insufficiency. Gentian Diagnostics ASA was founded in 2001 and is headquartered in Moss, Norway.
GENTIAN DIAGNOST. NO -01 management
6- Mr. Matti HeinonenChief Executive Officer
- Mr. Njaal KindCFO & COO
- Mr. Frank FrantzenChief Technology Officer · born 1957
- Dr. Aleksandra HavelkaChief Scientific Officer
- Mr. Markus JaquemarChief Growth Officer
- Dr. Tom NilsenHead of Product Development